• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms, Castration-Resistant - 22 Studies Found

Not yet recruiting : Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)
: Prostatic Cancer, Castration-Resistant
: 2016-08-08
: Drug: SXL01
Completed : Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
: Prostate Cancer
: 2015-04-15
:
  • Biological: Dendritic cell based cryoimmunotherapy

Recruiting : Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
: Metastatic Castration-Resistant Prostatic Cancer
: 2014-09-30
:
  • Drug: cabazitaxel Cabazitaxel

Terminated : F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
: Castration-resistant Prostate Cancer
: 2013-08-01
: Device: F-Choline-PET
Completed : Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
:
  • Hormone Resistant Prostate Cancer
  • Metastatic Prostate Cancer

: 2007-10-09
:
  • Drug: docetaxel 35mg/m² o

Not yet recruiting : Combination Study of Guadecitabine and Pembrolizumab.
:
  • Castration-Resistant Prostatic Cancer
  • Non Small Cell Lung Cancer

: 2016-11-02
:
  • Drug: Guadecitabine In arm 1 (

Completed : Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
: Castration-Resistant Prostatic Cancer
: 2015-03-20
: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223) Dosage and treatment duration according to the decisio
Completed : Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy
:
: 2025-08-02
: To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer
NOT_YET_RECRUITING : Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2025-08-02
: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
ACTIVE_NOT_RECRUITING : A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
: Prostatic Neoplasms, Castration-Resistant
: 2025-08-02
: As provided in real-world setting
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.